Zepbound (tirzepatide)

Zepbound (Tirzepatide)

Zepbound contains tirzepatide, a medicine that acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Tirzepatide is used as part of a comprehensive approach to weight management alongside a reduced-calorie diet and increased physical activity.

What is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. These hormones are involved in appetite regulation, glucose metabolism and other metabolic processes. Treatment with tirzepatide may help eligible patients reduce food intake and support weight management when combined with appropriate lifestyle measures.

Zepbound and UK Regulatory Status

UK regulatory information identifies Mounjaro as a tirzepatide medicine authorised for the treatment of obesity and weight management. MHRA records also associate the name Zepbound with tirzepatide.

For a UK-facing product page, do not imply that the Zepbound brand itself has a separate UK marketing authorisation unless this has been independently verified. Where appropriate, distinguish between the internationally marketed Zepbound brand and the UK-authorised tirzepatide product.

See the MHRA information on tirzepatide and Mounjaro for official UK regulatory information.

How Tirzepatide Works

Tirzepatide activates GIP and GLP-1 receptors. These pathways are involved in appetite, satiety and blood-glucose regulation. Its effects can help reduce calorie intake and support weight management when treatment is combined with dietary and physical-activity measures.

Dose Information

Tirzepatide treatment uses gradual dose escalation. The appropriate starting dose, escalation schedule and maintenance dose depend on the authorised product and the indication being treated.

Do not use a dose schedule from an overseas Zepbound product as a substitute for the current UK prescribing information. Patients should follow the dosing instructions provided by their UK prescriber and the official product information for the medicine supplied.

Important Safety Information

• Tirzepatide is a prescription medicine and should be used under appropriate healthcare supervision.
• Common adverse effects can include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, constipation and abdominal discomfort.
• Tell your healthcare professional about all medicines you take and any relevant medical conditions.
• People taking medicines that can cause hypoglycaemia, such as insulin or sulfonylureas, may require particular medical supervision.
• Seek medical advice if you experience severe or persistent abdominal pain or other serious symptoms.
• Do not change the prescribed dose or treatment schedule without speaking with your healthcare professional.

Product Information

• Active ingredient: Tirzepatide
• Drug class: GIP and GLP-1 receptor agonist
• Administration: Subcutaneous injection
• Therapeutic area: Metabolic/weight management
• UK prescription status: Prescription medicine

Related Products

For related information, visit our Mounjaro (tirzepatide) page and our Weight Management Guide.

You can also explore our Weight Management category for related prescription weight-management information.

Official UK Resources

For UK regulatory information, consult the Medicines and Healthcare products Regulatory Agency (MHRA).

The MHRA authorised Mounjaro (tirzepatide) for weight management in eligible adults in the UK in 2023. Current MHRA records continue to identify tirzepatide and Mounjaro in relation to obesity treatment.

Frequently Asked Questions

What is Zepbound?

Zepbound is a brand name associated with tirzepatide, a dual GIP and GLP-1 receptor agonist used for weight management in eligible patients.

What is the active ingredient in Zepbound?

The active ingredient is tirzepatide.

Is Zepbound authorised in the UK?

UK regulatory records identify Mounjaro as the authorised tirzepatide product for obesity treatment. The specific UK status of the Zepbound brand should be verified before making availability or marketing-authorisation claims.

How does tirzepatide work?

Tirzepatide activates GIP and GLP-1 receptors, pathways involved in appetite regulation and glucose metabolism.

Is tirzepatide prescription only?

Tirzepatide medicines used for weight management are prescription medicines and should be used under appropriate healthcare supervision.

Can I change my tirzepatide dose myself?

No. Dose changes should only be made according to the prescribing information and advice of your healthcare professional.

Where can I find official UK information?

The MHRA and the official UK product information provide authoritative information about authorised tirzepatide medicines and their approved uses.